Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month […]